Bromantane
Nootropics
View productCompare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
Also known as: 9-Me-BC, 9-MBC, 9mebc, 9-mebc, 9-MeBC, 9 Me BC, 9-Methyl-β-carboline, 9-methyl-beta-carboline
9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253]. It is best understood as an experimental research chemical: there are no human trials, no human pharmacokinetic or safety data, and it is not approved for human use.
Half-life: Not characterized in humans (no pharmacokinetic data)MW: 182.22 g/mol (C12H10N2)CAS: 2521-07-56 PubMed results
Last reviewed:
Overview
At A Glance
Mechanism
9-Me-BC is a synthetic 9-methylated -carboline (pyridoindole) alkaloid. Unlike most -carbolines, which tend to be neurotoxic, 9-Me-BC shows a distinctive dopaminergic-supportive profile in preclinical models, acting through several linked mechanisms:…
Half-Life
Not characterized in humans (no pharmacokinetic data).
Dosing
Typically once daily (morning) in community reports; frequently cycled rather than taken continuously.
Dose Range
Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists.
Potential Benefits
Preclinical dopaminergic support: in rodent and cell-culture studies 9-Me-BC increased tyrosine hydroxylase expression and the number of differentiated dopamine neurons [PMID:17913302, PMID:20374418]Cognitive/learning signal in rodents: 10 days of dosing improved spatial learning and raised hippocampal dopamine with dendritic and synaptic growth in rats [PMID:22380576]Neuroprotective/neurorestorative in animal Parkinson's models: restored dopamine and substantia-nigra neuron counts after MPP+ injury and boosted mitochondrial complex I activity [PMID:20360614]Anti-inflammatory and neurotrophic actions in preclinical models: reduced microglial activation and induced neurotrophic factors such as BDNF, CDNF and artemin [PMID:20374418, PMID:32285253]Community-reported (anecdotal, unverified) motivation, drive, focus and mood lift - not demonstrated in any human study
Safety Notes
Common
Insomnia if dosed late in the day (anecdotal)Overstimulation, anxiety or headache at higher intakes (anecdotal)
Overview
9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253]. It is best understood as an experimental research chemical: there are no human trials, no human pharmacokinetic or safety data, and it is not approved for human use. Community dosing is entirely anecdotal, and because 9-Me-BC inhibits MAO-A it warrants MAOI-style caution. Research use only.
Potential Research Fields
Parkinson's diseaseDopaminergic neurodegenerationDepressionCognitive enhancement
What to Expect
- •This is a preclinical research chemical: all mechanistic and efficacy evidence comes from rodent and cell-culture work by a small number of research groups - there are zero human trials.
- •Community users describe a stimulant-like lift in focus, motivation and mood, often the same day; these reports are anecdotal and unverified.
- •Onset and half-life in humans are unknown, so the timing and duration of any effect cannot be stated reliably.
- •Because it inhibits MAO-A in vitro, users treat it with MAOI-style caution: no serotonergic-drug stacking and mind tyramine-rich foods.
- •No long-term human safety data exist - the honest expectation is uncertainty.
Individual responses vary. Timeline based on commonly reported research observations.
Chemical Information
IUPAC Name
9-methyl-9H-pyrido[3,4-b]indole
CAS Number
2521-07-5
Molecular Formula
C12H10N2
Molecular Mass
182.22 g/mol
Dosing & Protocols
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- Route and how often
- A titration schedule
- Beginner, intermediate and advanced protocols
- Reconstitution and handling notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Research
Unlock the research summary
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- A summary of the key research
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Interactions
Interaction Matrix
Contraindications
Precautionary (there is no human data to define true contraindications): avoid combining with SSRIs, SNRIs, MAOIs, other serotonergic drugs, or sympathomimetic stimulants due to 9-Me-BC's in-vitro MAO-A inhibition and the theoretical serotonin-toxicity / hypertensive (tyramine) risk. Not for use in pregnancy or breastfeeding, in anyone with significant cardiovascular or hepatic disease, or alongside prescription medications, given the complete absence of human safety testing. Research use only - not for human consumption.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
Best Price
$54.99
Best $/mg
—
Vendors
1
Listings
1
capsule
Form
Sort
Current low
$54.99
current listings
7-day low
—
not enough history yet
30-day low
—
not enough history yet
30-day change
—
not enough history yet
Tracking since Jul 1, 2026 · 1 data point
Vendors Selling 9-Me-BC (9-Methyl-β-carboline)
How we score these vendors
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllAniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
PreclinicalView Profile
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
PreclinicalView Profile
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
34 PubMedView Profile
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
PreclinicalView Profile
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
1 PubMedView Profile
Fasoracetam (NS-105)
NootropicsPhase 2Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.
t½ Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039).
PreclinicalView Profile
View Full Dosage Guide →
Protocols, calculator & safety for 9-Me-BC (9-Methyl-β-carboline)
Research Score
61
6 PubMed results
Quality Indicators
Data Completeness
100%Description
Mechanism of Action
Chemical Data
Dosing Protocols
Safety Profile
PubMed Results
Interactions
Vendor Listings
COA Verification
41
Verified COAs
1
Vendors w/ COA
High verification rate (95%)
Latest test: 10/6/2026
Research Volume
6PubMed results
Limited research available
Quick Facts
Half-Life
Not characterized in humans (no pharmacokinetic data).
Molecular Weight
182.22 g/mol
CAS Number
2521-07-5
Trial Phase
Preclinical
Safety Profile
Risk Not EstablishedCommon Side Effects
- • Insomnia if dosed late in the day (anecdotal)
- • Overstimulation, anxiety or headache at higher intakes (anecdotal)
Stop Use If
- Do not combine with SSRIs, SNRIs, MAOIs, MDMA or other serotonergic drugs
- Avoid in pregnancy/breastfeeding and with cardiovascular or liver disease
- Discontinue and seek care if signs of serotonin toxicity (agitation, rapid heartbeat, high temperature, tremor) occur
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Is 9-Me-BC safe for humans?
Unknown. There are no human safety studies, no clinical trials and no human pharmacokinetic data - every safety statement about 9-Me-BC is extrapolated from rodent/cell-culture work or from community anecdote. It is a research chemical (RUO), not an approved supplement or drug.
Is 9-Me-BC an MAO inhibitor?
In vitro, yes - it inhibits MAO-A with an IC50 around 1 uM and MAO-B around 15.5 uM [PMID:32285253]. That potency is why the community treats it with MAOI-style caution: avoid stacking it with SSRIs/SNRIs, other MAOIs or serotonergic supplements, and be mindful of tyramine-rich (aged/fermented) foods. These interactions are theoretical for 9-Me-BC specifically - they have not been formally documented in people.
What does the research actually show?
Dopaminergic, neuroprotective, neurorestorative and anti-inflammatory effects in rodents and cell cultures - including improved spatial learning and higher hippocampal dopamine in rats [PMID:22380576] and restoration of dopamine neurons in an MPP+ Parkinson's model [PMID:20360614]. None of this has been reproduced in humans, so it cannot be assumed to translate.
How do people dose it?
Anecdotally, roughly 5-25 mg once daily by mouth, usually in the morning and often cycled rather than taken continuously. There is no validated human dose - these figures come from nootropic forums, not clinical dosing studies.
Can I take it with my antidepressant?
You should not combine 9-Me-BC with SSRIs, SNRIs, MAOIs or other serotonergic medications. Because it inhibits MAO-A in vitro, combining it with serotonergic drugs carries a theoretical risk of serotonin toxicity. Talk to a clinician; do not self-combine.
Is 9-Me-BC approved or legal as a supplement?
No. It is not an approved drug or dietary supplement and is sold only as a research chemical for laboratory use (RUO). Legal status varies by country.
How many vendors sell 9-Me-BC (9-Methyl-β-carboline), and what does it cost per mg?
1 of the vendors BodyHackGuide tracks list 9-Me-BC (9-Methyl-β-carboline) (1 listing). The lowest listed price BodyHackGuide has recorded for 9-Me-BC (9-Methyl-β-carboline) is $54.99. No 9-Me-BC (9-Methyl-β-carboline) listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for 9-Me-BC (9-Methyl-β-carboline).
Which vendors have third-party COAs for 9-Me-BC (9-Methyl-β-carboline) on file at BodyHackGuide?
BodyHackGuide holds no third-party certificate records for 9-Me-BC (9-Methyl-β-carboline). Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor.
Research Tools
You may also like
Related Compounds
View AllAniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694).
PreclinicalView Profile
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773)
PreclinicalView Profile
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
34 PubMedView Profile
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
PreclinicalView Profile
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose)
1 PubMedView Profile
Fasoracetam (NS-105)
NootropicsPhase 2Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia.
t½ Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039).
PreclinicalView Profile
Research Benches
Reference pages that put 9-Me-BC (9-Methyl-β-carboline) next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.